KY1 completes first patient dosing in Phase I clinical trial
2024-10-25
Russian Academy of Engineering Foreign Academician Dr. Zhang Dan was Invited to Visit and Guide Clinical Trials
KeYe Biotech Successfully Holds KY1 Product Clinical Trial Kickoff Meeting
KeYe Biotech Receives "High Growth Enterprise" Designation
KeYe Life's KY1 molecule has received orphan drug designation (ODD) from the FDA for gastric cancer
2024-10-22
KeYe Life's KY1 molecule has received orphan drug designation from the FDA for hepatocellular carcinoma
